Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Newmont Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Newmont Corporation trades at $113.4 (market cap $121.80B). The key difference: Newmont Corporation is far larger — about 42.6× Dyne Therapeutics Inc. Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Newmont Corporation for 59 Days on average.
| DYN | NEM | |
|---|---|---|
Market Cap | $2.86B | $121.80B |
Volume | 3,341,579 | 4,383,120 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $135.14 |
52-Week Low | $14.60 | $78.63 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.18B | $118.39B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Newmont Corporation (NEM) trades at $115.59, down 1.33% on the day, as the gold mining giant demonstrates strong fundamental performance with record revenue of $22.67 billion in 2025 and net income of $7.09 billion. The stock shows a bullish technical trend with support at $115 and resistance at $118, while maintaining attractive valuation metrics including a P/E of 14.58 and ROE of 25.53%. Recent news highlights the company's record $5.3 billion free cash flow and focus on per-share growth through operational improvements.
Newmont presents a compelling investment case with strong analyst support (76% buy ratings) and a $136.83 consensus price target representing 18% upside. The company's transformation from losses in 2022-2023 to robust profitability, coupled with disciplined capital allocation and gold price tailwinds, supports continued growth. Key risks include gold price volatility, operational execution challenges, and broader market conditions that could pressure mining stocks despite strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
